Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients ...

Related Keywords

Saudi Arabia ,California ,United States ,Washington ,Columbus ,Ohio ,Boston ,Massachusetts ,Philadelphia ,Pennsylvania ,Chicago ,Illinois ,London ,City Of ,United Kingdom ,University Of Chicago ,Bahrain ,San Francisco ,Texas ,Ohio State University ,Australia ,Kelly Center ,San Antonio ,Switzerland ,Dallas ,Great Britain ,America ,Kingdom Of Saudi Arabia ,Saudi ,Stephan Grupp ,Reshma Kewalramani ,Samarth Kulkarni ,Los Angeles ,Ohio State University Comprehensive Cancer Center ,Vertex Pharmaceuticals Incorporated Nasdaq ,Solove Research Institute ,Children National Hospital ,Exchange Commission ,Vertex Pharmaceuticals ,Therapeutics Inc ,Instagram ,Linkedin ,Steering Committee ,Drug Agency ,Companies To Work ,Drug Administration ,Regulatory Agency ,University Of Chicago Comer Children Hospital ,Viacyte Inc ,National Health Regulatory Authority ,Facebook ,Boston Medical Center ,Youtube ,European Medicines Agency ,City Of Hope Children Cancer Center ,Nasdaq ,Vertex Pharmaceuticals Incorporated ,Chief Executive Officer ,Section Chief ,Cellular Therapy ,Transplant Section ,Steering Committee Chair ,Medical Center ,National Hospital ,Hope Children ,Cancer Center ,City Children ,Tristar Centennial ,James Cancer Hospital ,Comer Children ,Saudi Food ,Prescription Drug User Fee Act ,Financial Reporting ,Sickle Cell Disease ,Care Managers ,Prescribing Information ,Patient Information ,North America ,Top Employers ,Private Securities Litigation Reform Act ,